Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Failing the public health--rofecoxib, Merck, and the FDA.

Topol EJ.

N Engl J Med. 2004 Oct 21;351(17):1707-9. Epub 2004 Oct 6. No abstract available.

2.

Rofecoxib, Merck, and the FDA.

Kim PS, Reicin AS.

N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. No abstract available. Erratum in: N Engl J Med. 2005 Mar 17;352(11):1163.

3.

Rofecoxib, Merck, and the FDA.

Villalba L, Witter J.

N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. No abstract available.

PMID:
15625745
4.

Rofecoxib, Merck, and the FDA.

Wolfe MM.

N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. No abstract available.

PMID:
15625749
5.

Vioxx's history and the need for better procedures and better testing.

Gilhooley M.

Seton Hall Law Rev. 2007;37(4):941-68. No abstract available.

PMID:
18363218
6.

Lessons learned after the withdrawal of rofecoxib.

Giaquinta D.

Manag Care Interface. 2004 Nov;17(11):25-6, 46. No abstract available.

PMID:
15573801
7.

The sad story of Vioxx, and what we should learn from it.

Karha J, Topol EJ.

Cleve Clin J Med. 2004 Dec;71(12):933-4, 936, 938-9. No abstract available.

PMID:
15641522
8.

Drug safety special: the safety catch.

Wadman M.

Nature. 2005 Mar 31;434(7033):554-6. No abstract available.

PMID:
15800591
9.

FDA warns Merck over its promotion of rofecoxib.

Josefson D.

BMJ. 2001 Oct 6;323(7316):767. No abstract available.

10.

What ails the FDA?

Gorelick KJ.

N Engl J Med. 2005 Jun 16;352(24):2553-4. No abstract available.

11.

Learning the value of drugs--is rofecoxib a regulatory success story?

Eisenberg RS.

N Engl J Med. 2005 Mar 31;352(13):1285-7. No abstract available.

PMID:
15800222
12.

The Vioxx debacle.

Fielder JH.

IEEE Eng Med Biol Mag. 2005 Mar-Apr;24(2):106-9. No abstract available.

PMID:
15825852
13.

Bringing the FDA's Information to Market.

Woloshin S, Schwartz LM.

Arch Intern Med. 2009 Nov 23;169(21):1985-7. doi: 10.1001/archinternmed.2009.399. No abstract available.

PMID:
19933960
14.

Merck VIOXX "warning" is questioned.

Allen TS Jr, Henderson JH Jr.

Tex Med. 2005 May;101(5):5-6. No abstract available.

PMID:
15948521
15.

FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke.

Lenzer J.

BMJ. 2005 Feb 26;330(7489):440. No abstract available.

16.

NEJM editor gives pretrial evidence in Vioxx case.

Tanne JH.

BMJ. 2006 Feb 4;332(7536):255. No abstract available.

17.

Coxibs and cardiovascular disease.

Fitzgerald GA.

N Engl J Med. 2004 Oct 21;351(17):1709-11. Epub 2004 Oct 6. No abstract available.

18.

Raising the safety bar--the FDA's coxib meeting.

Okie S.

N Engl J Med. 2005 Mar 31;352(13):1283-5. No abstract available.

PMID:
15800221
19.

Evaluating drug effects in the post-Vioxx world: there must be a better way.

Avorn J.

Circulation. 2006 May 9;113(18):2173-6. No abstract available.

20.

Will Merck survive Vioxx?

Simons J, Stipp D.

Fortune. 2004 Nov 1;150(9):90-2, 94, 96-7 passim. No abstract available.

PMID:
15543824

Supplemental Content

Support Center